Gaithersburg, Maryland-based Emergent BioSolutions Inc., a specialty biopharmaceutical company, announced that it closed on the sale of its portfolio of travel vaccines to Bavarian Nordic. The transaction was initially announced on February 15, 2023.
The portfolio includes Vivotif and Vaxchora, which prevent typhoid fever and cholera, respectively. Emergent BioSolutions is also selling a Phase III vaccine candidate for the prevention of Chikungunya virus.
Emergent received $270 million and may receive up to an additional $110 million in potential future milestone payments.
Wells Fargo Securities, LLC served as financial advisor, and Barnes & Thornburg LLP served as legal counsel for Emergent BioSolutions.
Bavarian Nordic specializes in the research, development and manufacturing of cancer immunotherapies and vaccines for infectious diseases. The company is based in Kvistgard, Denmark and led by CEO Paul Chaplin.
According to data captured in the LevinPro HC database, 59 Biotechnology transactions have been announced in 2023. This is a 25% increase from the same time frame during 2022 (January 1, through May 15) when 46 Biotechnology acquisitions were reported.
